Monitoring of Parasite Kinetics in Indian Post–Kala-azar Dermal Leishmaniasis
暂无分享,去创建一个
[1] S. Sundar,et al. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress , 2017, PLoS neglected tropical diseases.
[2] D. Ghosh,et al. Infectivity of Post-Kala-azar Dermal Leishmaniasis Patients to Sand Flies: Revisiting a Proof of Concept in the Context of the Kala-azar Elimination Program in the Indian Subcontinent , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] P. Das,et al. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL) , 2017, PloS one.
[4] Thakur Cp. Is elimination of kala-azar feasible by 2017? , 2016 .
[5] E. Zijlstra. The immunology of post-kala-azar dermal leishmaniasis (PKDL) , 2016, Parasites & Vectors.
[6] S. Roy,et al. A male preponderance in patients with Indian post kala‐azar dermal leishmaniasis is associated with increased circulating levels of testosterone , 2016, International journal of dermatology.
[7] S. Selim,et al. A Study on Health Seeking Behaviors of Patients of Post-Kala-Azar Dermal Leishmaniasis , 2015, BioMed research international.
[8] P. Salotra,et al. Correction: Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India , 2015, PLoS neglected tropical diseases.
[9] D. Mukhopadhyay,et al. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis. , 2015, The American journal of tropical medicine and hygiene.
[10] P. Salotra,et al. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India , 2015, PLoS neglected tropical diseases.
[11] A. Maji,et al. PKDL—A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India , 2015, PLoS neglected tropical diseases.
[12] Jane E. Dalton,et al. M2 Polarization of Monocytes-Macrophages Is a Hallmark of Indian Post Kala-Azar Dermal Leishmaniasis , 2015, PLoS neglected tropical diseases.
[13] M. Ramam,et al. Histopathological characteristics of post kala-azar dermal leishmaniasis: a series of 88 patients. , 2015, Indian journal of dermatology, venereology and leprology.
[14] S. Sundar,et al. Parasite load estimation by qPCR differentiates between asymptomatic and symptomatic infection in Indian visceral leishmaniasis. , 2014, Diagnostic microbiology and infectious disease.
[15] Jane E. Dalton,et al. Post kala-azar dermal leishmaniasis: an unresolved mystery , 2014, Trends in parasitology.
[16] J. Beijnen,et al. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] S. Sundar,et al. Oral miltefosine for Indian post‐kala‐azar dermal leishmaniasis: a randomised trial , 2013, Tropical medicine & international health : TM & IH.
[18] S. Bhattacharya,et al. Endemic transmission of visceral leishmaniasis in Bhutan. , 2012, The American journal of tropical medicine and hygiene.
[19] S. Roy,et al. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. , 2011, The Journal of infectious diseases.
[20] D. Mondal,et al. Recent advances in post-kala-azar dermal leishmaniasis , 2011, Current opinion in infectious diseases.
[21] G. Katara,et al. Miltefosine as an effective choice in the treatment of post‐kala‐azar dermal leishmaniasis , 2011, The British journal of dermatology.
[22] S. Sundar,et al. Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. , 2011, The Journal of antimicrobial chemotherapy.
[23] S. Roy,et al. Case Report: Case Series of Misdiagnosis with rK39 Strip Test in Indian Leishmaniasis , 2011 .
[24] S. Pun,et al. Case report: Expansion of visceral leishmaniasis to the western hilly part of Nepal. , 2011, The American journal of tropical medicine and hygiene.
[25] R. Haque,et al. Enhanced Case Detection and Improved Diagnosis of PKDL in a Kala-azar-Endemic Area of Bangladesh , 2010, PLoS neglected tropical diseases.
[26] M. Chatterjee,et al. Post‐kala‐azar dermal leishmaniasis – an overview , 2010, International journal of dermatology.
[27] L. C. Singh,et al. Quantification of Parasite Load in Clinical Samples of Leishmaniasis Patients: IL-10 Level Correlates with Parasite Load in Visceral Leishmaniasis , 2010, PloS one.
[28] D. Mukhopadhyay,et al. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis. , 2010, The Journal of investigative dermatology.
[29] Shyam Sundar,et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. , 2010, The New England journal of medicine.
[30] Md. Mahmudur Rahman,et al. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] R. Peeling,et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[32] R. Peeling,et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? , 2007, Nature Reviews Microbiology.
[33] P. Salotra,et al. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. , 2006, The Indian journal of medical research.
[34] Shyam Sundar,et al. Oral miltefosine for Indian visceral leishmaniasis. , 2002, The New England journal of medicine.
[35] M. Rai,et al. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] Shyam Sundar,et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. , 2002, The Lancet. Infectious diseases.